modafinil has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 5 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study." | 9.17 | Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013) |
| "To examine the efficacy and safety of modafinil on parkinsonism and excessive daytime sleepiness (EDS), as well as on negative symptoms and cognitive abilities in patients with schizophrenia or schizoaffective disorder (DSM-IV criteria) in a randomized double-blind placebo-controlled 8-week study." | 5.17 | Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. ( Ancoli-Israel, S; Caligiuri, MP; Kash, TP; Liu, L; Lohr, JB; May, TA; Murphy, JD, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lohr, JB | 1 |
| Liu, L | 1 |
| Caligiuri, MP | 1 |
| Kash, TP | 1 |
| May, TA | 1 |
| Murphy, JD | 1 |
| Ancoli-Israel, S | 1 |
| van Vliet, SA | 3 |
| Vanwersch, RA | 3 |
| Jongsma, MJ | 3 |
| van der Gugten, J | 1 |
| Olivier, B | 3 |
| Philippens, IH | 3 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Montastruc, JL | 1 |
| Rascol, O | 1 |
1 trial available for modafinil and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzhydryl Compounds; Cognition Disorders; Disord | 2013 |
4 other studies available for modafinil and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Arousal; Benzhydryl Com | 2006 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Callithrix; Disease Models, A | 2008 |
Modafinil and pramipexole-associated somnolence.
Topics: Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants; Disor | 2001 |